Pro-resolving lipid mediators in the resolution of neointimal hyperplasia pathogenesis in atherosclerotic diseases

Area of Science:

• Cardiovascular Research
• Inflammation Biology
• Pharmacology

Background:

• Neointimal hyperplasia (NIH) and restenosis remain challenges in endovascular therapy for atherosclerotic diseases.
• Atherosclerosis and NIH are inflammatory processes, suggesting a role for endogenous lipid mediators.
• Specialized pro-resolving mediators (SPMs) are a class of lipids with potential to resolve inflammation.

Purpose of the Study:

• To review the role of SPMs in the context of NIH and atherosclerosis.
• To explore the mechanistic insights into SPM deficiency in these conditions.
• To evaluate the therapeutic potential of SPMs for combating NIH.

Main Methods:

• Review of existing literature on SPMs, atherosclerosis, and NIH.
• Analysis of mechanistic pathways involving SPMs, PDGF, and inflammatory cells.
• Evaluation of therapeutic strategies using SPMs.

Main Results:

• Endogenous SPM deficiency, linked to 12/15-lipoxygenase, contributes to resolution deficits in atherosclerosis and NIH.
• SPMs, particularly RvD1 and LXA4, attenuate NIH by inhibiting PDGF.
• SPMs promote resolution through anti-inflammatory actions on smooth muscle cells and macrophages, involving the ALX/FPR2 receptor.

Conclusions:

• SPMs offer a novel therapeutic strategy for NIH and restenosis by resolving inflammation.
• Targeting SPM pathways presents a promising approach to improve outcomes in endovascular therapy.
• Further research is needed to address mechanistic, pharmacokinetic, and anatomical considerations for clinical translation.